RORC

RORC encodes the nuclear receptor RORγt, a DNA-binding transcription factor that directs the effector programs of Th17 cells and innate lymphoid cells (PMID:24812667, PMID:35896601). The gene has a complex 11-exon structure in which the DNA-binding domain is encoded across two exons, each contributing a zinc finger (PMID:9403063). RORγt transcriptional activity drives IL-17 cytokine production, and selective small-molecule inverse agonists targeting its ligand-binding domain suppress IL-17 output in human primary cells (PMID:26048793). As a direct transcriptional regulator, RORγt binds the PTGER2 (EP2) promoter to repress prostaglandin receptor expression in Th17 cells, controlling the cellular response to PGE2 (PMID:24812667). RORC transcription is itself tightly controlled: NFAT proteins acting cooperatively with NF-κB bind regulatory elements at the RORC locus to activate RORγt expression downstream of T cell receptor stimulation, with P300/CBP recruitment and acetylation marking these elements (PMID:31619674), and RORα cooperatively binds a Rorc cis-regulatory element to sustain RORγt expression and Th17 effector function through a positive feedback loop (PMID:36243007). In innate lymphoid cell differentiation, Notch signaling upregulates RORC, which through its target IL-23R enables ILC3 effector functions (PMID:35896601).

1. 1997 High

   Established the foundational genomic architecture of RORC, defining it as a zinc-finger nuclear receptor with a DNA-binding domain split across two exons, anchoring it within the nuclear receptor structural framework.

   Evidence Genomic cloning of P1 vector clones, exon mapping, and FISH in mouse and human

   PMID:9403063

   Open questions at the time

   • Does not address transcriptional targets or cellular function
   • No tissue-specific expression or isoform function defined
2. 2014 High

   Identified RORγt as a direct transcriptional repressor of PTGER2 in Th17 cells, linking the receptor to control of the cellular PGE2 response rather than purely activating function.

   Evidence ChIP-seq for RORγt binding plus RORC knockdown with EP2 expression readout in human Th17 cells

   PMID:24812667

   Open questions at the time

   • Mechanism of repression (cofactor recruitment) not defined
   • Does not establish the full target gene repertoire
3. 2014 Low

   Synthesized RORγt as a druggable nuclear receptor whose ligand-binding domain accommodates inverse agonists that suppress IL-17, framing its therapeutic tractability.

   Evidence Review summarizing RORc LBD structural biology, IL-17 reporter assays, and medicinal chemistry

   PMID:24502334

   Open questions at the time

   • Review without primary experiments; mechanistic claims drawn from undescribed sources
   • No single defined structural or binding dataset
4. 2015 Medium

   Confirmed with selective tool compounds that RORc transcriptional activity directly drives IL-17 production, establishing a causal mechanistic link rather than correlation.

   Evidence Selective imidazopyridine/pyrimidine inverse agonists (>300-fold selectivity) in nuclear receptor panels and IL-17 assays in human primary cells

   PMID:26048793

   Open questions at the time

   • Pharmacological inhibition; does not map direct IL-17 locus binding
   • Off-target contributions in primary cells not fully excluded
5. 2019 High

   Defined the upstream control of RORC transcription, showing NFAT cooperates with NF-κB to activate the locus downstream of TCR signaling via chromatin remodeling.

   Evidence CRISPR/Cas9 deletion of RORC regulatory elements, ChIP, cyclosporine A inhibition, and P300/CBP recruitment analysis in CD4+ T cells

   PMID:31619674

   Open questions at the time

   • Does not resolve how NFAT/NF-κB integrate with other Th17 cues
   • Quantitative contribution of each element to expression not partitioned
6. 2022 High

   Revealed RORα as a non-redundant co-regulator that reinforces RORC expression through cooperative binding to a Rorc cis-regulatory element, defining a positive feedback loop sustaining Th17 effector function.

   Evidence Genetic deletion of RORα in T cells, identification of the cis-regulatory element, cooperative binding analysis, and in vivo Th17 assays

   PMID:36243007

   Open questions at the time

   • Does not establish whether RORα binding alters local chromatin state
   • Tissue-specific dependence beyond peripheral effector sites unclear
7. 2022 Medium

   Positioned RORC downstream of Notch signaling in human ILC differentiation, with the RORC→IL-23R axis required for ILC3 effector functions, extending RORγt biology beyond adaptive T cells.

   Evidence Single-cell clonal analysis, RORC-deficient patient samples, and pharmacological Notch/IL-23 interference with cytokine assays

   PMID:35896601

   Open questions at the time

   • Notch→RORC step inferred from expression rather than direct binding evidence
   • Single lab; molecular link between Notch effectors and RORC locus undefined
8. 2022 Medium

   Connected α-synuclein to RORC induction in CD4+ T cells, linking the receptor's transcriptional upregulation to Th17 expansion, Treg destabilization, and neurodegeneration in a Parkinson's model.

   Evidence In vitro α-Syn stimulation with RORC mRNA quantification and GSK805 RORγt inhibitor rescue in MPTP mice with flow cytometry

   PMID:36343753

   Open questions at the time

   • No direct binding or ChIP data; transcriptional upregulation mechanism inferred from inhibitor rescue
   • Single lab; pathway placement of α-Syn relative to RORC indirect

• How RORγt selects between activating (IL-17, IL-23R) and repressive (PTGER2) target programs, and the full cofactor logic governing its locus regulation, remains unresolved.
• No comprehensive direct target map across cell types
• Coactivator/corepressor switching mechanism undefined
• Structural basis of ligand-dependent transcriptional output not integrated with target selection